Boosting NAD(+) blunts TLR4-induced type I IFN in control and systemic lupus erythematosus monocytes

BACKGROUND: Fasting and NAD(+)-boosting compounds, including NAD(+) precursor nicotinamide riboside (NR), confer antiinflammatory effects. However, the underlying mechanisms and therapeutic potential are incompletely defined. METHODS: We explored the underlying biology in myeloid cells from healthy...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jing, Singh, Komudi, Lin, Amy, Meadows, Allison M., Wu, Kaiyuan, Shing, Vivian, Bley, Maximilian, Hassanzadeh, Shahin, Huffstutler, Rebecca D., Schmidt, Mark S., Blanco, Luz P., Tian, Rong, Brenner, Charles, Pirooznia, Mehdi, Kaplan, Mariana J., Sack, Michael N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884917/
https://www.ncbi.nlm.nih.gov/pubmed/35025762
http://dx.doi.org/10.1172/JCI139828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884917/
https://www.ncbi.nlm.nih.gov/pubmed/35025762
http://dx.doi.org/10.1172/JCI139828

Ejemplares similares